Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seladelpar for Ischemic Cholangiopathy
NCT07305363Phase 2Not yet recruiting
- Sponsor
- University of California, San Diego
- Start
- May 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of seladelpar in ischemic cholangiopathy (IC), sponsored by University of California, San Diego. Primary endpoint: Serum alkaline phosphatase at 26 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
seladelpar
03
Conditions
ischemic cholangiopathy (IC)
Beyond the preview
Go deeper on NCT07305363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07305363.